BR112022022869A2 - Composições de polipeptídeo de fusão de il-2 e métodos de fabricação e uso destas - Google Patents
Composições de polipeptídeo de fusão de il-2 e métodos de fabricação e uso destasInfo
- Publication number
- BR112022022869A2 BR112022022869A2 BR112022022869A BR112022022869A BR112022022869A2 BR 112022022869 A2 BR112022022869 A2 BR 112022022869A2 BR 112022022869 A BR112022022869 A BR 112022022869A BR 112022022869 A BR112022022869 A BR 112022022869A BR 112022022869 A2 BR112022022869 A2 BR 112022022869A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- manufacturing
- fusion polypeptide
- polypeptide compositions
- compositions
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000004927 fusion Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 102000000588 Interleukin-2 Human genes 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022860P | 2020-05-11 | 2020-05-11 | |
| PCT/US2021/031616 WO2021231319A1 (en) | 2020-05-11 | 2021-05-10 | Il-2 fusion polypeptide compositions and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022869A2 true BR112022022869A2 (pt) | 2023-01-31 |
Family
ID=78524880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022869A BR112022022869A2 (pt) | 2020-05-11 | 2021-05-10 | Composições de polipeptídeo de fusão de il-2 e métodos de fabricação e uso destas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210395325A1 (https=) |
| EP (1) | EP4149514A4 (https=) |
| JP (1) | JP2023526024A (https=) |
| KR (1) | KR20230008759A (https=) |
| CN (1) | CN115867307A (https=) |
| AU (1) | AU2021269585A1 (https=) |
| BR (1) | BR112022022869A2 (https=) |
| CA (1) | CA3172874A1 (https=) |
| IL (1) | IL298064A (https=) |
| MX (1) | MX2022014163A (https=) |
| TW (1) | TW202207971A (https=) |
| WO (1) | WO2021231319A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61391B1 (sr) * | 2012-06-08 | 2021-02-26 | Alkermes Pharma Ireland Ltd | Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti |
| EA202092926A3 (ru) * | 2014-03-24 | 2021-10-29 | Биовератив Терапьютикс Инк. | Лиофилизированные составы, содержащие фактор ix |
| AU2015364396B2 (en) * | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| MX2019013142A (es) * | 2017-05-05 | 2019-12-16 | Amgen Inc | Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion. |
| UA125971C2 (uk) * | 2017-07-25 | 2022-07-20 | Джянгсу Хенгруй Медісін Ко., Лтд. | Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування |
| MX2022004577A (es) * | 2019-10-18 | 2022-05-10 | Alkermes Pharma Ireland Ltd | Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune. |
-
2021
- 2021-05-10 MX MX2022014163A patent/MX2022014163A/es unknown
- 2021-05-10 BR BR112022022869A patent/BR112022022869A2/pt unknown
- 2021-05-10 KR KR1020227041366A patent/KR20230008759A/ko active Pending
- 2021-05-10 CN CN202180040284.5A patent/CN115867307A/zh active Pending
- 2021-05-10 AU AU2021269585A patent/AU2021269585A1/en not_active Abandoned
- 2021-05-10 CA CA3172874A patent/CA3172874A1/en active Pending
- 2021-05-10 US US17/315,974 patent/US20210395325A1/en not_active Abandoned
- 2021-05-10 EP EP21804274.5A patent/EP4149514A4/en active Pending
- 2021-05-10 JP JP2022568632A patent/JP2023526024A/ja active Pending
- 2021-05-10 IL IL298064A patent/IL298064A/en unknown
- 2021-05-10 WO PCT/US2021/031616 patent/WO2021231319A1/en not_active Ceased
- 2021-05-11 TW TW110116904A patent/TW202207971A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4149514A1 (en) | 2023-03-22 |
| JP2023526024A (ja) | 2023-06-20 |
| MX2022014163A (es) | 2023-02-22 |
| AU2021269585A1 (en) | 2022-12-15 |
| EP4149514A4 (en) | 2024-06-26 |
| US20210395325A1 (en) | 2021-12-23 |
| TW202207971A (zh) | 2022-03-01 |
| CA3172874A1 (en) | 2021-11-18 |
| CN115867307A (zh) | 2023-03-28 |
| KR20230008759A (ko) | 2023-01-16 |
| WO2021231319A1 (en) | 2021-11-18 |
| IL298064A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115024A1 (es) | PROTEÍNAS DE FUSIÓN INTERLEUCINA-2 / RECEPTOR a DE INTERLEUCINA-2 Y MÉTODOS DE USO | |
| CO2025009073A2 (es) | Compuestos cíclicos fusionados y uso de los mismos | |
| CL2021001779A1 (es) | Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos | |
| AR122863A1 (es) | Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos | |
| CO2021009695A2 (es) | Conjugados de il-2 y métodos de uso de este | |
| AR114445A1 (es) | Conjugados de il-15, y sus usos | |
| MX2024014691A (es) | Enlazadores de conjugacion mejorados | |
| AR112969A1 (es) | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas | |
| BR112021026376A2 (pt) | Proteínas de fusão flt3l-fc e métodos de uso | |
| MX2022002111A (es) | Novedosos anticuerpos anti-cldn18.2. | |
| SA521421825B1 (ar) | (glp1) البروتينات الاندماجية المتمثلة في الببتيد 1 الشبيه بالجلوكاجون (gdf15) وعامل تمايز النمو 15 واستخدامه | |
| MX2024003535A (es) | Proteina mutante de interleucina-2 y fusion de la misma. | |
| CO2022008004A2 (es) | Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos | |
| BR112022005426A2 (pt) | Polipeptídeos de fusão dap10/dap12 | |
| PH12022550326A1 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
| WO2021188374A9 (en) | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides | |
| MX2021005759A (es) | Plataformas, productos y metodos para la expresion en endosporas. | |
| BR112022022869A2 (pt) | Composições de polipeptídeo de fusão de il-2 e métodos de fabricação e uso destas | |
| MX2023011262A (es) | Composiciones que comprenden polipeptidos de fusion nkg2d, cxcr2 y dap10/dap12 y metodos de uso de los mismos. | |
| MX2021012964A (es) | Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15. | |
| BR112022022764A2 (pt) | Composições de polipeptídeo de fusão de il-2 e métodos para fazer e usar as mesmas | |
| EP4466012A4 (en) | CHIMERA POLYPEPTIDES | |
| EP4466011A4 (en) | CHIMERA POLYPEPTIDES | |
| EP4466013A4 (en) | CHIMERA POLYPEPTIDES | |
| PE20200495A1 (es) | Proteinas recombinantes robo2, composiciones, metodos y usos de las mismas |